Last $4.99 USD
Change Today -0.09 / -1.77%
Volume 894.4K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. - Special Call

To discuss FDA's Relistor(R) Appeal Response

Progenics Pharmaceuticals, Inc. Elects Paul J. Maddon as Director

Progenics Pharmaceuticals, Inc. elected Paul J. Maddon as director at its AGM held on June 17, 2014.

Progenics Pharmaceuticals, Inc. - Special Call

To discuss on FDA Advisory Committee meeting

Progenics Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2014

Progenics Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2014.

Progenics Pharmaceuticals, Inc. Provides Updated Positive Results from Phase 2 Study in Prostate Cancer

Progenics Pharmaceuticals, Inc. announced that results from its phase 2 trial of PSMA ADC have been chosen to be included in the genitourinary (prostate) cancer poster highlights session at the annual meeting of the American Society of Clinical Oncology being held in Chicago, Illinois on May 30 - June 3. These data update previously presented results from a study of 83 patients with metastatic castrate-resistant prostate cancer who suffered from progressive disease despite treatment with at least one taxane-containing chemotherapy. A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC). PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of prostate specific membrane antigen (PSMA), a protein that is a clinically validated biomarker of prostate cancer and which is expressed on the surface of prostate cancer cells. The PSMA antibody is linked to monomethyl auristatin E, a chemotherapeutic drug that inhibits cell proliferation by disrupting the cellular backbone required for replication. The resultant antibody-drug conjugate attaches to the PSMA protein on the surface of prostate cancer cells and is designed to internalize into the cancer cell, release active anti-cancer drug, and destroy the malignant cell.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $4.99 USD -0.09

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dynavax Technologies Corp $1.37 USD -0.01
Genocea Biosciences Inc $17.31 USD -0.72
Peregrine Pharmaceuticals Inc $1.52 USD -0.03
Rigel Pharmaceuticals Inc $3.27 USD -0.05
ZIOPHARM Oncology Inc $3.09 USD -0.07
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.6x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.